Lyell Immunopharma Inc (LYEL)
2.045
-0.06
(-3.08%)
USD |
NASDAQ |
Jun 25, 16:00
2.00
-0.04
(-2.20%)
Pre-Market: 08:52
Lyell Immunopharma Enterprise Value: -6.224M for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | -6.224M |
| June 24, 2024 | 11.62M |
| June 21, 2024 | -3.675M |
| June 20, 2024 | 3.974M |
| June 18, 2024 | 9.072M |
| June 17, 2024 | 26.92M |
| June 14, 2024 | 75.36M |
| June 13, 2024 | 133.99M |
| June 12, 2024 | 126.34M |
| June 11, 2024 | 113.60M |
| June 10, 2024 | 75.36M |
| June 07, 2024 | 93.20M |
| June 06, 2024 | 105.95M |
| June 05, 2024 | 156.94M |
| June 04, 2024 | 108.50M |
| June 03, 2024 | 146.74M |
| May 31, 2024 | 179.88M |
| May 30, 2024 | 151.84M |
| May 29, 2024 | 126.34M |
| May 28, 2024 | 174.78M |
| May 24, 2024 | 179.88M |
| May 23, 2024 | 164.59M |
| May 22, 2024 | 177.33M |
| May 21, 2024 | 139.09M |
| May 20, 2024 | 154.39M |
| Date | Value |
|---|---|
| May 17, 2024 | 172.23M |
| May 16, 2024 | 182.43M |
| May 15, 2024 | 139.09M |
| May 14, 2024 | 121.25M |
| May 13, 2024 | 85.55M |
| May 10, 2024 | 100.85M |
| May 09, 2024 | 156.94M |
| May 08, 2024 | 111.05M |
| May 07, 2024 | 121.25M |
| May 06, 2024 | 121.25M |
| May 03, 2024 | 75.36M |
| May 02, 2024 | 85.55M |
| May 01, 2024 | 67.70M |
| April 30, 2024 | 26.91M |
| April 29, 2024 | 47.31M |
| April 26, 2024 | 26.91M |
| April 25, 2024 | 34.56M |
| April 24, 2024 | 60.05M |
| April 23, 2024 | 95.75M |
| April 22, 2024 | 88.10M |
| April 19, 2024 | 42.21M |
| April 18, 2024 | 67.70M |
| April 17, 2024 | 80.45M |
| April 16, 2024 | 88.10M |
| April 15, 2024 | 85.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-231.76M
Minimum
Sep 20 2023
4.507B
Maximum
Jun 17 2021
721.09M
Average
242.21M
Median
Enterprise Value Benchmarks
| GlycoMimetics Inc | -9.750M |
| Candel Therapeutics Inc | 162.07M |
| Eliem Therapeutics Inc | 103.55M |
| Entrada Therapeutics Inc | 169.52M |
| NovaBay Pharmaceuticals Inc | 2.939M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -60.67M |
| Revenue (Quarterly) | 0.003M |
| Total Expenses (Quarterly) | 55.58M |
| EPS Diluted (Quarterly) | -0.24 |
| Profit Margin (Quarterly) | -2.02M% |
| Earnings Yield | -44.12% |
| Normalized Earnings Yield | -41.04 |